A Phase I Trial of SS1 (dsFv) PE38 With Paclitaxel, Carboplatin, and Bevacizumab in Subjects With Unresectable Non-Small Cell Lung Adenocarcinoma

Model scores of the 29,894 trials active now.

Model score 20% for any early termination, 8% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 24% of the time (231 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2011-09-28. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: cellnon smalllung cancercoronaryto determine
  Phrases that lowered it: participantsproteincyclethe studyopen
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: 6.5% (lowers risk) · Sponsor's track record
• Phase: 1 (lowers risk) · Design
• Maximum age: 100 (lowers risk) · Who can join
• Trials the sponsor started in the prior 2 years: 218 (lowers risk) · Sponsor's track record
• Disease area, cancer: Yes (raises risk) · Disease area
• Design: single group (raises risk) · Design
• Responsible party: not given (raises risk) · Design
• Drug's FAERS reports with a death: 17.1% (lowers risk) · Drug's FDA history
• Sponsor's past trials: 336 (lowers risk) · Sponsor's track record
• Has a data monitoring committee: not given (lowers risk) · Design
• Number of arms: not given (lowers risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Primary purpose: treatment (raises risk) · Design
• Disease area, respiratory: Yes (raises risk) · Disease area
• Sponsor type: government (raises risk) · Sponsor's track record
• Drug's FAERS reports marked serious: 91.8% (raises risk) · Drug's FDA history
• Drug's FAERS reports before start: 25283 (raises risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma NCT01362790 · started 2011 · scored riskier than 82% of active trials completed
• Trial of Poor Performance Status Patients (ToPPS) NCT00892710 · started 2009 · scored riskier than 68% of active trials completed
• A Study of SHR-1210 in Combination With Pemetrexed and Carboplatin in Subjects With Non-squamous NSCLC NCT03134872 · started 2017 · scored riskier than 38% of active trials completed
• A Personal Cancer Vaccine (NEO-PV-01) With Pembrolizumab and Chemotherapy for Patients With Lung Cancer NCT03380871 · started 2018 · scored riskier than 65% of active trials completed
• A Study Evaluating The Safety, Tolerability, Pharmacokinetics, And Efficacy Of Venetoclax In Combination With Atezolizumab, Carboplatin, And Etoposide In Participants With Untreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC). NCT04422210 · started 2020 · scored riskier than 29% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.